#VisualAbstract: Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
Tag: adjuvant immunotherapy
Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma
Click to read this study in The Lancet Oncology.
Adjuvant pembrolizumab improved distant-metastasis free survival and lowered risk of recurrence in melanoma patients
1. In the pembrolizumab arm, distant metastasis-free survival was significantly improved and the risk of recurrence remained lower than the ...
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage melanoma
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage melanoma There was no significant difference in ...
Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients
1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in PD-L1 unselected non-small-cell lung cancer patients who underwent ...